Stereotactic radiation may offer better outcomes in nine cancersOctober 24, 2019New data suggests a specific advanced radiation treatment protocol is leading to better survival outcomes than other therapy options for at least nine tumor types. That's according to PetCure Oncology, which presented its findings at the recent Veterinary Cancer Society Annual Conference (VCS) in Houston, Tex. The pet cancer care provider says nine of the 11 tumor types it studied showed increased median survival time relative to the current body of peer-reviewed published literature for pets treated with stereotactic radiation/stereotactic radiation therapy (SRS/SRT), an advanced form of radiation therapy used in human medicine. The list of tumor types includes brain, nasal, osteosarcoma (bone tumors), mast cell, and melanoma. "We have now treated more than 3,000 pets on-protocol with radiation therapy, including more than 2,200 with stereotactic radiation," says PetCure's chief medical officer, Neal Mauldin, DVM, DACVIM (internal medicine and oncology), DACVR (radiation oncology). "The good news is that many of them are still alive and thriving, so the data is still maturing. But objective analysis of the preliminary data at this point suggests stereotactic radiation can be considered a standard of care for the treatment of many tumor types, much like it already is in human cancer treatment. This …
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
PetCure Oncology marks 3,000 cancer treatmentsSeptember 26, 2019Cancer care company PetCure Oncology hit a milestone this week with the treatment of its 3,000th patient.
Cancer treatment company plans for public offeringJuly 25, 2019PetCure Oncology has engaged Boustead Securities for a Regulation D 506(c) offering.
PetCure Oncology plans 30 hospitalsJuly 28, 2016PetCure Oncology, which rolled out stereotactic radiosurgery for cancer-stricken pets just over a year ago, has big expansion plans.
